OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis $11.44 +0.74 (+6.92%) As of 09/17/2026 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and TrendsShort Interest About Santen Pharmaceutical Stock (OTCMKTS:SNPHY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Santen Pharmaceutical alerts:Sign Up Key Stats Today's Range$11.32▼$11.5150-Day Range$10.70▼$13.8052-Week Range$9.22▼$13.93Volume1,523 shsAverage Volume1,469 shsMarket Capitalization$3.69 billionP/E RatioN/ADividend Yield1.22%Price TargetN/AConsensus RatingHold Company Overview Santen Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and commercializes prescription eye-care medicines and related products for conditions affecting vision and ocular health. Its portfolio includes treatments for glaucoma and ocular hypertension, dry eye disease, retinal disorders, eye infections and allergies, as well as other ophthalmic conditions. Santen also conducts research in areas such as regenerative medicine and other therapies intended to address unmet needs in eye care. Founded in Japan in 1890, Santen has expanded beyond its domestic market and serves patients and healthcare professionals across Asia, Europe and other international markets. The company distributes products through regional operations and partnerships, with Japan remaining an important base for its research, development and commercial activities.AI Generated. May Contain Errors. Read More Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNPHY Stock News HeadlinesSanten Pharmaceutical Co Stock Price HistorySeptember 3, 2026 | investing.comSanten Pharmaceutical Co., Ltd. GAAP EPS of ¥22.30, revenue of ¥68.9BAugust 6, 2026 | seekingalpha.comNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing to do with chips or ChatGPT. Huang says AI is moving off computers and into the real world, calling it the dawn of a new industrial revolution. Matt McCall, who flagged NVDA at $6 before it climbed 3,100% in six years, reveals his top pick in this emerging space.September 18 at 1:00 AM | Monument Traders Alliance (Ad)Santen boosts profits in Q1 and maintains upbeat full-year outlookAugust 6, 2026 | tipranks.comSanten Pharmaceutical Co Ltd ADR SNPHYMay 14, 2026 | morningstar.comMSanten Pharmaceutical Co., - Depositary Receipt (SNPHY) Price Target Decreased by 10.74% to 13.32November 9, 2025 | msn.comSanten Pharmaceutical 1H Net Y13.94B Vs Net Y18.77BNovember 6, 2025 | marketwatch.comSanten Pharmaceutical to Cancel 19.8 Million Treasury SharesNovember 6, 2025 | tipranks.comSee More Headlines SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed this year? Santen Pharmaceutical's stock was trading at $10.30 at the beginning of the year. Since then, SNPHY shares have increased by 11.1% and is now trading at $11.44. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/18/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:SNPHY CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,144Year Founded1890Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares322,290,000Free FloatN/AMarket Cap$3.69 billion OptionableNot Optionable BetaN/A Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:SNPHY) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Santen Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPHY Stock Alerts